Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

Journal of Clinical Oncology

Volumn 28, Issue 3, 2010, Pages 412-417

  Nowakowski, Grzegorz S ^a   Maurer, Matthew J ^a   Habermann, Thomas M ^a   Ansell, Stephen M ^a   Macon, William R ^a   Ristow, Kay M ^a   Allmer, Cristine ^a   Slager, Susan L ^a   Witzig, Thomas E ^a   Cerhan, James R ^a  

^a Mayo Clinic

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MEVINOLIN; PRAVASTATIN; PREDNISONE; RITUXIMAB; ROSUVASTATIN; SIMVASTATIN; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; DRUG ANTAGONISM; DRUG RESPONSE; DRUG USE; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; DRUG INTERACTION; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PROGNOSIS;

EID: 75749117568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.4245     Document Type: Article

References (36)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
2. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005
3. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
4. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
5. Pfreundschuh M, Trumper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
6. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
7. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
8. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
9. Salles GA, Foussard C, Nicolas M, et al: Rituximab added to alphaIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOEL-AMS FL-2000 randomized trial in 359 patients. Blood 104:49a-50a, 2004 (abstr 160)
10. Hochster H, Weller E, Gascoyne RD, et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study. J Clin Oncol 27:1607-1614, 2009
11. Mann D, Reynolds K, Smith D, et al: Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42:1208-1215, 2008
12. Endo A: The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 5:67-80, 2004
13. Pérez-Sala D, Mollinedo F: Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209-1215, 1994
14. Zhuang L, Kim J, Adam RM, et al: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115:959-968, 2005
15. Jakobisiak M, Golab J: Potential antitumor effects of statins. Int J Oncol 23:1055-1069, 2003
16. Caraglia M, Budillon A, Tagliaferri P, et al: Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: Preclinical and clinical implications. Curr Drug Targets 6:301-323, 2005
17. van der Spek E, Bloem AC, van de Donk NW, et al: Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91:542-545, 2006
18. Winiarska M, Bil J, Wilczek E, et al: Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5:e64, 2008
19. Rabinowitz I: Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 26:5486, 2008
20. Goldstein MR, Mascitelli L, Pezzetta F: Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 360:192, 2009
21. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland, WHO, 2008
22. US Food and Drug Administration: Drugs@ FDA. http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm
23. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer, 2000
27. Anonymous: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
28. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
29. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626, 2008
30. Han X, Kilfoy B, Zheng T, et al: Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 19:841-858, 2008
31. Moreau AS, Jia X, Patterson CJ, et al: The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenström macroglobulinaemia. Br J Haematol 142:775-785, 2008
32. Sarrabayrouse G, Synaeve C, Leveque K, et al: Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia 9:1078-1090, 2007
33. Mausner-Fainberg K, Luboshits G, Mor A, et al: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 197:829-839, 2008
34. Schramm R, Menger MD, Harder Y, et al: Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology 120:315-324, 2007
35. Dave SS: Follicular lymphoma and the micro-environment. Blood 111:4427-4428, 2008
36. Kuppers R: Prognosis in follicular lymphoma: It's in the microenvironment. N Engl J Med 351: 2152-2153, 2004